Low-Dose Naltrexone (LDN) for Autoimmune Disease: The Evidence by Condition

What It Is

Why It's Proposed as an Immune Modulator

Naltrexone at its conventional dose, 50 to 100 mg, is an FDA-approved opioid receptor antagonist used for opioid and alcohol use disorder. At low doses, typically 0.5 to 6 mg per day and most often studied at 4.5 mg, it appears to behave differently, a dose-response pattern called hormesis. It isn't manufactured commercially at these doses, so it has to come from a compounding pharmacy with a prescription.

Three mechanisms have been proposed for how it might work as an anti-inflammatory or immune-modulating agent, in order of how well they're actually characterized. The best supported is Toll-like receptor 4 (TLR4) antagonism on microglial and immune cells, which dampens pro-inflammatory signaling through a pathway independent of the opioid system entirely. The second is transient, six-to-eight-hour blockade of opioid receptors that triggers a compensatory rebound in the body's own endorphins and enkephalins, which have immune-regulating effects of their own. The third is temporary blockade of the opioid growth factor receptor, which drives compensatory upregulation of that receptor and its ligand, a pathway involved in regulating cell proliferation.

All three mechanisms remain largely theoretical. Clinical use of LDN has outpaced the mechanistic research explaining it. It's also worth knowing that some of the mechanistic studies behind ultra-low-dose naltrexone, doses far below the 0.5 to 6 mg range discussed here, have since been retracted over concerns about data integrity. That retraction doesn't affect the low-dose range or the trials below, but it's a reason to be skeptical of mechanism claims made for those much smaller, unregulated doses specifically.

The Evidence

Condition by Condition, Graded Separately

Crohn's Disease

Smith JP, Field D, Bingaman SI, Evans R, Mauger DT. "Safety and tolerability of low-dose naltrexone therapy in children with moderate to severe Crohn's disease: a pilot study." Journal of Clinical Gastroenterology. 2013;47(4):339–345. PMID: 23188075. A randomized, placebo-controlled pediatric trial found that eight weeks of LDN produced a significant reduction in disease activity and improved quality of life compared to placebo. Open-label adult data separately report clinical response in the large majority of treated patients over similar timeframes. These are still small studies with short follow-up, but they're genuine randomized, placebo-controlled findings, not case reports.

Randomized, Placebo-Controlled, Pediatric · Endpoint: Disease Activity, Quality of Life · Small Sample, Short Follow-Up

Multiple Sclerosis

Cree BAC, Kornyeyeva E, Goodin DS. "Pilot trial of low-dose naltrexone and quality of life in multiple sclerosis." Annals of Neurology. 2010;68(2):145–150. PMID: 20695007. A placebo-controlled crossover trial of 60 patients found a significant improvement in mental health-related quality of life on LDN versus placebo. Sharafaddinzadeh N, Moghtaderi A, Kashipazha D, Majdinasab N, Shalbafan B. "The effect of low-dose naltrexone on quality of life of patients with multiple sclerosis: a randomized placebo-controlled trial." Multiple Sclerosis. 2010;16(8):964–969. PMID: 20534644. A larger trial of 96 patients, using the same 4.5 mg dose, found no benefit on quality of life at all. Neither trial measured disease progression itself, MRI lesion activity or relapse rate, only subjective quality-of-life scores, so even the positive result doesn't speak to whether LDN affects the underlying disease.

Randomized, Placebo-Controlled (Both) · Endpoint: Quality of Life Only, Not Disease Progression · Mixed Results Between Trials

Fibromyalgia

Younger J, Noor N, McCue R, Mackey S. "Low-dose naltrexone for the treatment of fibromyalgia: findings of a small, randomized, double-blind, placebo-controlled, counterbalanced, crossover trial." Arthritis & Rheumatism. 2013;65(2):529–538. PMID: 23359310. This original trial, and a 31-person follow-up by the same research group, found meaningful pain reduction and improved mood versus placebo. Due Bruun K, Christensen R, Amris K, et al. "Naltrexone 6 mg once daily versus placebo in women with fibromyalgia: a randomised, double-blind, placebo-controlled trial." Lancet Rheumatology. 2024;6(1):e31–e39. PMID: 38258677. The two most recent and largest trials, including this one in a considerably higher-tier journal than where the earlier positive results appeared, found no statistically significant benefit over placebo on the primary pain outcome. That pattern, early positive findings that don't replicate once a larger, better-designed trial is run, is exactly what the most current comprehensive review of the entire LDN literature describes across nearly every condition it covers (Gouda et al., 2026).

Randomized, Placebo-Controlled (All) · Endpoint: Pain, Mood · Early Positive Findings Did Not Replicate in Larger, Later, Higher-Tier Trials

Other Autoimmune and Inflammatory Uses

Outside Crohn's disease and MS, the evidence drops to case-report and case-series level for almost everything else it gets used for. In Sjogren's syndrome, only three case reports exist, describing improved musculoskeletal pain and fatigue but no change in the hallmark dry eye and dry mouth symptoms. In psoriasis, a case series and one larger open cohort of 71 patients report reduced severity and improved quality-of-life scores, but neither was placebo-controlled. Osteoarthritis and inflammatory arthritis were tested together in one placebo-controlled trial, which found no significant benefit. For most other autoimmune and inflammatory skin conditions LDN gets used for, the evidence is case reports and small case series without a single randomized trial behind them.

Case-Report / Case-Series Level for Most · One Placebo-Controlled Trial (OA/Inflammatory Arthritis), Negative

Hashimoto's Thyroiditis

There is no published clinical trial, and no published case series identifiable in the most current comprehensive review of the LDN literature, 105 studies reviewed through February 2026, testing LDN in Hashimoto's thyroiditis or autoimmune thyroid disease specifically. What has circulated so far is anecdotal reports of benefit, plus extrapolation from the general TLR4 and anti-inflammatory mechanism above and the modest, inconsistent benefit seen in other autoimmune conditions like Crohn's and MS. That mechanistic case has been judged strong enough to warrant formal testing: a registered Phase 2 randomized controlled trial, ThyroLDN (ACTRN12625000131459), is currently underway at St. Vincent's Hospital Sydney, evaluating 4.5 mg LDN daily for six months in a target of 150 patients with Hashimoto's thyroiditis. Its primary outcome is thyroid-specific quality of life, and it also tracks thyroid peroxidase antibody titre as a secondary outcome, meaning it's testing the autoimmune process itself and not just symptoms. As of its most recent registry update the trial is actively recruiting, with results not expected before spring 2027.

No Published Trial or Case Series to Date · Phase 2 RCT (ThyroLDN) Currently Recruiting, Results Not Expected Before Spring 2027 · Anecdotal Evidence Only Until Then

Honest Limits

What the Evidence Doesn't Support, Condition by Condition

If you have Crohn's disease, there's real, if early-stage, randomized evidence worth discussing. If you have MS, the evidence is genuinely mixed even on quality of life alone, and says nothing about disease progression. If you have fibromyalgia, the most rigorous recent trials didn't beat placebo, regardless of what the original studies found. If you have Hashimoto's or another autoimmune condition not covered by a trial above, this would mean extrapolating from mechanism and from other diseases' data, not from evidence in your actual condition. None of that makes LDN unreasonable to consider in a treatment-resistant case. It's inexpensive and generally safe, and the most current comprehensive review of the evidence concludes it can have a pragmatic role in treatment-resistant cases where standard therapies have failed, provided its experimental status and uncertain efficacy are made clear from the start rather than framed as a proven immune modulator.

Off-label; not FDA-approved for autoimmune or inflammatory conditions.

Sources

References